Dokter W et al: "Abstract 4329: Novel HER2 targeting antibody-drug conjugates based on DNA-interacting duocarmycin and an unique linker technology with great potential in breast cancer and NSCLC", , 15 April 2013 (2013-04-15), XP002725434, Retrieved from the Internet: URL:http://cancerres.aacrjournals.org/cgi/ content/meeting_abstract/73/8_MeetingAbstr acts/4329?sid=79046d57-942d-4258-9aed-2238 d480704d [retrieved on 2014-06-05] (B1)

WO-A2-2011/133039 (B1)

JOHN A. FLYGARE ET AL: "Antibody-Drug Conjugates for the Treatment of Cancer", CHEMICAL BIOLOGY & DRUG DESIGN, vol. 81, no. 1, 17 January 2013 (2013-01-17), pages 113-121, XP055121985, ISSN: 1747-0277, DOI: 10.1111/cbdd.12085 (B1)

NOLTING B: "Linker technologies for antibody-drug conjugates", METHODS IN MOLECULAR BIOLOGY - ANTIBODY-DRUG CONJUGATES 2013 HUMANA PRESS USA, vol. 1045, 2013, pages 71-100, XP008169796, ISSN: 1064-3745 (B1)

RAJALETCHUMY VELOO KUTTY ET AL: "Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers", BIOMATERIALS, vol. 34, no. 38, 1 December 2013 (2013-12-01), pages 10160-10171, XP055122815, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2013.09.043 (B1)

REBECCA K KELLY ET AL: "An antibodycytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 47, no. 11, 28 February 2011 (2011-02-28), pages 1736-1746, XP028323640, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2011.02.023 [retrieved on 2011-03-03] (B1)

S. A. KAZANE ET AL: "Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 10, 6 March 2012 (2012-03-06), pages 3731-3736, XP055076255, ISSN: 0027-8424, DOI: 10.1073/pnas.1120682109 (B1)

SHEN B -Q ET AL: "Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates", NATURE BIOTECHNOLOGY 2012 NATURE PUBLISHING GROUP USA, vol. 30, no. 2, February 2012 (2012-02), pages 184-189, XP055123129, ISSN: 1087-0156 (B1)

Synthon company: "Synthon Biopharmaceuticals reports positive early results with its second generation HER2-antibody-drug conjugate", , 22 January 2013 (2013-01-22), XP002725428, Retrieved from the Internet: URL:http://www.synthon.com/Corporate/News/ PressReleases/Synthon-reports-positive-ear ly-results-with-its-second-generation-HER2 -antibody-drug-conjugate [retrieved on 2014-06-05] (B1)

TRAIL P A: "Antibody drug conjugates as cancer therapeutics", ANTIBODIES 20130227 MDPI AG CHE, vol. 2, no. 1, 27 February 2013 (2013-02-27), pages 113-129, XP002725437, (B1)

WO-A1-02/096910 (B1)

WO-A1-2012/143523 (B1)

WO-A2-03/026577 (B1)

WO-A2-2004/032828 (B1)

EP-A1- 2 380 909 (B1)